Please use this identifier to cite or link to this item:
|Title:||Blood eosinophils and outcomes in severe hospitalised exacerbations of COPD|
Greening, Neil James
Harvey-Dunstan, Theresa C.
Williams, Johanna E. A.
Morgan, Michael D.
Brightling, Christopher E.
Hussain, S. F.
Pavord, I. D.
Singh, Sally J.
Steiner, Michael C.
|Publisher:||Elsevier, American College of Chest Physicians (ACCP)|
|Citation:||Chest, 2016, doi:10.1016/j.chest.2016.01.026|
|Abstract:||BACKGROUND: Patients with moderate exacerbations of chronic obstructive pulmonary disease (COPD) and the eosinophilic phenotype have better outcomes with prednisolone. Whether this is the case in patients hospitalised with a severe exacerbation of COPD is unclear. We investigate the rate of recovery of eosinophilic and non-eosinophilic exacerbations from subjects participating in a multi-centre randomised control trial assessing health outcomes in hospitalised exacerbations (clinical trial registration ISRCTN05557928). METHODS: Subjects were recruited at presentation to hospital with an exacerbation of COPD and stratified into eosinophilic exacerbations if the peripheral blood eosinophil on admission was ≥200 cells/μL and/or ≥2% of the total leukocyte count. Admission details, serum CRP, length of stay and subsequent re-hospitalisation were compared between groups. RESULTS: We recruited 243 COPD subjects (117 males) with a mean age (range) of 71 years (45-93). The inpatient mortality rate was 3% (median time to death 12 days, range 9-16). The median absolute eosinophil count was 100 cells/μL (range 10 to 1500 cells/μL) and 25% met our criteria for an eosinophilic exacerbation. In this population, the mean length of stay was shorter than in patients with non-eosinophilic exacerbations (5.0 (1-19) vs. 6.5 (1-33), p=0.015) following treatment with oral corticosteroids and independent of treatment prior to admission. Readmission rates at 12 months was similar between the groups. CONCLUSIONS: Patients presenting to hospital with a severe eosinophilic exacerbation of COPD have a shorter length of stay. These exacerbations are usually not associated with an elevated CRP, suggesting that better treatment stratification of exacerbations can be utilised.|
|Embargo on file until:||3-Feb-2020|
|Rights:||Copyright © 2016 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.|
|Description:||The file associated with this record is under a 48mth embargo while its copyright status is ascertained. The full text may be available through the publisher links above.|
|Appears in Collections:||Published Articles, Dept. of Infection, Immunity and Inflammation|
Files in This Item:
|Eosinophil paper submitted Chest.docx||Post-review (final submitted)||273.5 kB||Unknown||View/Open|
|Eosinophil paper submitted Chest.pdf||Post-review (final submitted)||409.58 kB||Adobe PDF||View/Open|
Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.